Examining Optimal Management of Warfarin and DOAC-Associated Bleeding in Emergency Situations
CSL Behring.
Faculty Presenter
William E. Dager PharmD, BCPS
Pharmacist Specialist
UC Davis Medical Center
Clinical Professor of Pharmacy
UC San Francisco School of Pharmacy
Clinical Professor of Medicine
UC Davis School of Medicine
Sacramento, California
Program Description
Approximately 6 million patients in the United States are prescribed anticoagulants annually, and the number of candidates for anticoagulation is expected to grow as the population ages. With an increasing population on warfarin or DOACs comes a risk of bleeding and situations requiring reversal of anticoagulation depending on the clinical scenario. The American College of Cardiology recommends that a pharmacist be consulted in the event a patient requires an anticoagulant reversal agent, so it is essential to understand the appropriate role of these agents. Pharmacists should have a familiarity with the guidelines, laboratory assessments, and nuances of each of the agents used in the management of warfarin or DOAC-associated bleeds to ensure patients are properly managed.
Target audience: Health-system pharmacists
Type of activity: Application
Release date: February 9, 2021
Expiration date: June 17, 2022
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Determine clinical challenges that occur with emergency-related warfarin and DOAC-associated bleeding
- Examine the role, efficacy, and safety of reversal agents for the management of warfarin and DOAC-associated emergency bleeds
- Identify the use of INR levels to dose anticoagulants appropriately and the drug-drug interactions among anticoagulants and associated agents
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-21-070-H01-P. The activity is available for CE credit through June 17, 2021.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webinar in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Faculty
William E. Dager PharmD, BCPS has no relevant financial relationships with commercial interests to disclose
The following contributors have no relevant financial relationships with commercial interests to disclose:
Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Dipti Desai, PharmD, CHCP; Liza Patel, PharmD, RPh; Nicole Grassano; Kelly McCormick; Susan Pordon; and Brianna Winters.
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
Privacy Policy and Terms of Use Information:
